









Humber Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on July 2024

Classification of products:

Status	Description
 GREEN	Medicines suitable for routine use within primary care and Secondary care. May be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies
 AMB 1	Specialist recommendation: These medicines are considered suitable for GP prescribing following specialist recommendation or via an APC approved prescribing guideline.
 AMB 2	Specialist initiation: These medicines are considered suitable for GP prescribing following specialist initiation, including titration of dose and assessment of efficacy. These medicines may also have an APC approved guideline to aid GPs in further prescribing.
 AMB SCP	AMBER SHARE CARE PROTOCOL- Specialist initiation with ongoing monitoring: Medicines that must be initiated by a specialist, and which require significant monitoring on an ongoing basis. Full agreement to share the care of each specific patient must be reached under the shared care protocol which must be provided to the GP. If a commissioned shared care is not available in CCG/place then these drugs must be treated as red drug (hospital only).
 RED	Red-Hospital initiation and continuation only
 GREY	GREY- NON FORMULARY (As agreed by Area Prescribing Committee)
 PURPLE	To be supplied from the appropriate commissioned provider.
 NR	Not routinely commissioned

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
Nil this month				
2) New Requests				
Deucravacitinib (Sotyktu)	RED			TA907
Atogepant (Equipta)	AMB 2			TA973 – awaiting commissioning position
Levonorgestrel 20 micrograms/24 hours (Benilexa® One Handed)	PURPLE			For CHCP sexual health/contraceptive service. 6-month trial with feedback to committee.
3) New formulations & extensions to use				

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Nil this month				
4) Products considered by NICE				
TA967: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner
TA970: Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner
TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner
TA974: Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner
TA975: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner
TA977: Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner
HST31: Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner
5) Appeals against earlier decisions by the APC				
Nil this month				
6) Miscellaneous formulary decisions by the APC				

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Nil this month				

The following guidelines and pathways were presented to and approved at the July 2024 meeting of the APC:

- Blood Glucose meter formulary (updated)

The following Drug information leaflets were presented to and approved at the July 2024 meeting of the APC:

- Nil this month

The following shared care guidelines were presented to and approved at the July 2024 meeting of the APC:

- Sodium Valproate SCF

Other documents presented to and approved at the July 2024 meeting of the APC:

- Nil this month